Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Metastatic Malignant Neoplasm: early-phase trial registry

2 of 16 indexed Metastatic Malignant Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 2 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Metastatic Malignant Neoplasm: 16 US clinical trials tracked, 2 recruiting.

Metastatic Malignant Neoplasm is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.

Enrollment posture brief

Registry condition metastatic-malignant-neoplasm

OPEN 2 | RECR 13% | LATE 3 | EARLY 8 | RANK #1060 | SPON 12

Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)

Adolescent62.5%Alcohol Intoxication56.3%AL Amyloidosis43.8%Allergy18.8%Metastatic Malignant Neo (th…13%
Open-enrollment share among volume-matched conditions near Metastatic Malignant Neoplasm

Metastatic Malignant Neoplasm lists 2 open slots (13% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Malignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Malignant Neoplasm is recruiting below its size-band peers.

    2 of 16 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Metastatic Malignant Neoplasm research.

    M.D. Anderson Cancer Center accounts for 12 of 16 trials (75%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Metastatic Malignant Neoplasm enrolment sits around 144 participants.

    Median target enrolment is 144 among the 16 trials that report a genuine target (sentinel values excluded). 5 of those (31.3%) plan for fewer than 100 participants.

  4. Metastatic Malignant Neoplasm research is mostly interventional.

    14 interventional and 2 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 26Phase 33

Open and recent trials

16 total, page 1 of 1

RECRUITING Phase 2 1,500 participants

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Roswell Park Cancer Institute

NCT04068649

RECRUITING Phase 1 144 participants

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NextPoint Therapeutics

NCT06240728

ACTIVE NOT RECRUITING Phase 2 1,362 participants

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

M.D. Anderson Cancer Center

NCT02152254

ACTIVE NOT RECRUITING NA 406 participants

Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center

M.D. Anderson Cancer Center

NCT03671226

ACTIVE NOT RECRUITING Phase 3 212 participants

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

M.D. Anderson Cancer Center

NCT03525873

ACTIVE NOT RECRUITING Phase 2 150 participants

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

M.D. Anderson Cancer Center

NCT02286687

ACTIVE NOT RECRUITING 141 participants

Financial Distress in Advanced Cancer Patients

M.D. Anderson Cancer Center

NCT04053517

ACTIVE NOT RECRUITING Phase 2 110 participants

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

NCT03743649

ACTIVE NOT RECRUITING Phase 2 90 participants

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center

NCT02491632

ACTIVE NOT RECRUITING Phase 3 88 participants

Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases

M.D. Anderson Cancer Center

NCT01592968

ACTIVE NOT RECRUITING Phase 2 70 participants

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

NCT03021486

ACTIVE NOT RECRUITING NA 15 participants

Cryoablation for the Treatment of Metastatic Cancer

M.D. Anderson Cancer Center

NCT04150939

COMPLETED 351 participants

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

M.D. Anderson Cancer Center

NCT04186884

COMPLETED Phase 3 300 participants

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

NCT02585713

COMPLETED NA 125 participants

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

M.D. Anderson Cancer Center

NCT03856060

COMPLETED Phase 1 12 participants

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

University of Chicago

NCT02540876

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6
Phase 3 3

Named interventions

Most-linked intervention names on Metastatic Malignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
9 trials
Quality-of-Life Assessment Other
8 trials
Laboratory Biomarker Analysis Other
4 trials
Haloperidol Drug
2 trials
Placebo Other
2 trials
Ilorasertib Drug
1 trials
Dalteparin Drug
1 trials
Physical Activity Other
1 trials

US sites by state

Facility locations filed on Metastatic Malignant Neoplasm trials. A trial with sites in several states counts in each.

Texas 13 trials
Virginia 2 trials
New York 2 trials
Illinois 2 trials
South Dakota 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New Hampshire 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Malignant Neoplasm page

16 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Malignant Neoplasm condition card totals 16 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.